Mutation of histidine 874 in the androgen receptor ligand-binding domain leads to promiscuous ligand activation and altered p160 coactivator interactions

scientific article published on 4 August 2005

Mutation of histidine 874 in the androgen receptor ligand-binding domain leads to promiscuous ligand activation and altered p160 coactivator interactions is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1210/ME.2005-0231
P8608Fatcat IDrelease_jmwlcfjogjbubfv64yew3wh4i4
P698PubMed publication ID16081517
P5875ResearchGate publication ID7677605

P2093author name stringIain J McEwan
Jennifer Duff
P433issue12
P921main subjectligand bindingQ61659151
P304page(s)2943-2954
P577publication date2005-08-04
P1433published inMolecular EndocrinologyQ3319475
P1476titleMutation of histidine 874 in the androgen receptor ligand-binding domain leads to promiscuous ligand activation and altered p160 coactivator interactions
P478volume19

Reverse relations

cites work (P2860)
Q90626761A Targeted Bivalent Androgen Receptor Binding Compound for Prostate Cancer Therapy
Q37210787A novel androgen receptor amino terminal region reveals two classes of amino/carboxyl interaction-deficient variants with divergent capacity to activate responsive sites in chromatin
Q38534949Androgen receptor aberrations in the era of abiraterone and enzalutamide
Q38116575Androgen receptor modulators: a marriage of chemistry and biology
Q38977288Androgen receptor variation affects prostate cancer progression and drug resistance
Q36905832BAY 1024767 blocks androgen receptor mutants found in castration-resistant prostate cancer patients
Q58708797Characterization of Precursor-Dependent Steroidogenesis in Human Prostate Cancer Models
Q92091276Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models
Q38844202Development and exploitation of a novel mutant androgen receptor modelling strategy to identify new targets for advanced prostate cancer therapy
Q28534575Differential effects of genistein on prostate cancer cells depend on mutational status of the androgen receptor
Q39355407Down-regulation of calcium/calmodulin-dependent protein kinase kinase 2 by androgen deprivation induces castration-resistant prostate cancer
Q53282043Dynamic rewiring of the androgen receptor protein interaction network correlates with prostate cancer clinical outcomes.
Q42069568Efficacy of Immediate Switching from Bicalutamide to Flutamide as Second-Line Combined Androgen Blockade.
Q36508759Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients
Q33984776Intrinsic disorder in the androgen receptor: identification, characterisation and drugability
Q46882539Mechanisms of androgen receptor activation in advanced prostate cancer: differential co-activator recruitment and gene expression.
Q27646416Modulation of Androgen Receptor Activation Function 2 by Testosterone and Dihydrotestosterone
Q57112111Molecular Subtypes of Prostate Cancer
Q40386419Neofunctionalization of Androgen Receptor by Gain-of-Function Mutations in Teleost Fish Lineage.
Q37272639Pleiotropic functional properties of androgen receptor mutants in prostate cancer.
Q55439000Precision medicine applications in prostate cancer.
Q88817029Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making
Q26773613Prostate cancer metastasis: roles of recruitment and reprogramming, cell signal network and three-dimensional growth characteristics
Q37142544RNA editing of androgen receptor gene transcripts in prostate cancer cells
Q34495028Recent advances in allosteric androgen receptor inhibitors for the potential treatment of castration-resistant prostate cancer.
Q39642231Regulation of the androgen receptor by SET9-mediated methylation
Q53393993Resistance to Hormonal Therapy in Prostate Cancer.
Q38309205Switching and withdrawing hormonal agents for castration-resistant prostate cancer.
Q37577716The Drosophila Accessory Gland as a Model for Prostate Cancer and Other Pathologies
Q34189517The impact of point mutations in the human androgen receptor: classification of mutations on the basis of transcriptional activity
Q37590123The role of androgen receptor mutations in prostate cancer progression.
Q37726336The roles and action mechanisms of p160/SRC coactivators and the ANCCA coregulator in cancer
Q38140106The transcriptional programme of the androgen receptor (AR) in prostate cancer
Q26795611Therapy escape mechanisms in the malignant prostate
Q33745234Tumor suppressor function of androgen receptor coactivator ARA70alpha in prostate cancer
Q38259197Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level
Q38925848Wild-type and specific mutant androgen receptor mediates transcription via 17β-estradiol in sex hormone-sensitive cancer cells.

Search more.